Certain cyclic carbonyl compounds used in the prophylaxis of allergic conditions
AssigneeBurroughs Wellcome Co.
InventorJohn Henry Gorvin
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition and method for inhibiting the symptoms of allergic conditions such as asthma or allergic rhinitis which comprises administering a compound of the formula ##STR1## where Z.sup.2 is in the 6 position, wherein Z.sup.1 and Z.sup.2 are carboxylate, a pharmaceutically acceptable carboxylate salt, alkyl carboxylate, carboxamide, N-alkyl carboxamide, or N,N,-dialkylcarboxamide where alkyl in the above has 1 to 6 carbon atoms.
Claims24
A method of inhibiting the symptoms of asthma or allergic rhinitis in a mammal susceptible to asthma or allergic rhinitis, which comprises administration to said mammal of a prophylactically effective anti-asthma or anti-allergic rhinitis non toxic dose of a compound of formula (I) ##STR23## wherein Z.sup.1 is carboxyl, a pharmaceutically acceptable carboxylate salt, alkyl carboxylate, carboxamide, N-alkyl carboxamide or N,N-dialkylcarboxamide, and Z.sup.2 is a substituent in the 6-position selected from the meanings of Z.sup.1 as defined, wherein the "alkyl" moiety of alkyl carboxylate, N-alkylcarboxamide and N,N-dialkyl carboxamide has 1 to 6 carbon atoms.
A method of preventing the symptoms of allergic asthma in a human comprising pulmonary administration to the human of from 30 .mu.g to 0.3 mg, per kg. bodyweight of said human, of disodium xanthone-2,6-dicarboxylate, in the form of a powder having a particle size in the range from 0.5 to 7.mu..
A method for the prevention of the symptoms of hayfever in a human comprising administration to the human of from 2 .mu.g. to 6 mg. per kg. bodyweight of said human, of disodium xanthone-2,6-dicarboxylate.
A method for the prophylaxis of allergic asthma in a human, comprising pulmonary administration to said human of a prophylactically effective anti-allergic dose of disodium xanthone-2,6-dicarboxylate in association with an effective bronchodilating dose of a bronchodilator.
A method for prophylaxis of allergic rhinitis or asthma of a mammal comprising pulmonary administration to the mammal of a prophylactically effective anti-allergic dose of disodium xanthone-2,6-dicarboxylate in the form of a powder having a particle size in the range of 0.5 to 7 .mu..
A method for the prophylaxis of allergic rhinitis, asthma, urticaria, eczema or conjunctivitis of a mammal comprising administration to the mammal of a prophylactically effective anti-allergic dose of a tricyclic compound of formula ##STR24## wherein Z.sup.1 is a pharmaceutically acceptable carboxylate salt selected from the group consisting of a carboxylate salt with a potassium sodium, calcium, magnesium, ammonium, and organic base cation and Z.sup.2 is selected from the group consisting of Z.sup.1 as defined herein, carboxyl, alkyl carboxylate having 1 to 6 carbon atoms in the `alkyl` moiety, carboxamide and carboxamide N-substituted by alkyl having 1 to 6 carbon atoms.
A composition for the prophylaxis of an allergic condition selected from the group consisting of allergic rhinitis, asthma, urticaria, conjunctivitis and eczema of a mammal comprising a prophylactically effective non-toxic antiallergic amount of a tricyclic compound of formula ##STR25## wherein Z.sup.1 is a pharmaceutically acceptable carboxylate salt group selected from the group consisting of a carboxylate salt with a potassium, sodium, calcium, magnesium, ammonium and organic base cation and Z.sup.2 is selected from the group consisting of Z.sup.1 as defined herein, carboxyl alkyl carboxylate having 1 to 6 carbon atoms in the `alkyl` moiety, carboxamide and carboxamide N-substituted by alkyl having 1 to 6 carbon atoms, and a pharmaceutically acceptable salt carrier therefore.
A pharmaceutical composition for pulmonary administration to a mammal for inhibiting the symptoms of asthma or allergic rhinitis comprising an asthma or allergic rhinitis symptom inhibition effective non-toxic amount of disodium xanthone-2,6-dicarboxylate in the form of solid particles having a diameter of from 0.5 to 7.mu. and a pharmaceutically acceptable carrier therefore.
A composition for the prophylaxis of an allergic condition selected from the group consisting of allergic rhinitis, asthma, urticaria, conjunctivitis and eczema of a mammal comprising a prophylactically effective non-toxic anti-allergic amount of xanthone-2,6-dicarboxylic acid or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier therefor.
Dependencies are inferred from the claim text.